MARKET

MENS

MENS

Jyong Biotech Ltd.
NASDAQ
2.010
-0.070
-3.37%
After Hours: 2.010 0 0.00% 16:10 05/15 EDT
OPEN
2.090
PREV CLOSE
2.080
HIGH
2.090
LOW
1.991
VOLUME
55.20K
TURNOVER
--
52 WEEK HIGH
67.00
52 WEEK LOW
1.430
MARKET CAP
152.82M
P/E (TTM)
-115.5172
1D
5D
1M
3M
1Y
5Y
1D
Jyong Biotech FY25 net loss widens 55% to US$4.67 million
PUBT · 16h ago
Jyong Biotech Ltd. Files Annual Report on Form 20-F for Fiscal Year 2025
Barchart · 19h ago
Weekly Report: what happened at MENS last week (0504-0508)?
Weekly Report · 4d ago
Weekly Report: what happened at MENS last week (0427-0501)?
Weekly Report · 05/04 09:05
Jyong Biotech Delays Annual 20-F (Yearly Report)
TipRanks · 04/29 18:19
Jyong Biotech delays annual Form 20-F filing, cites audit completion needs
PUBT · 04/29 17:12
Jyong Biotech Updates Market Access Strategy for Innovative Botanical Drugs, Establishing Multiple Competitive Advantages for New Drug Portfolio
PR Newswire · 04/29 00:00
Jyong Biotech Advances Market Access Strategies For Its Plant-Based Drugs Botreso And PCP After Analysis Of Their Clinical Efficacy And Competitive Advantages
Benzinga · 04/28 12:37
More
About MENS
Jyong Biotech Ltd is a Taiwan-based science-driven biotechnology company. The Company is mainly engaged in developing and commercializing innovative and differentiated new drugs (plant-derived) mainly specializing in the treatment of urinary system diseases, with an initial focus on the markets of the United States (U.S.), the European Union (EU), and Asia. The Company has been developing a series of botanical drug candidates, including primary botanical drug candidate of MCS-2, another clinical-stage botanical drug candidate of PCP, and other preclinical-stage botanical drug candidates. MCS-2 is a new botanical drug candidate developed for treatment of benign prostate hyperplasia/lower urinary tract symptoms (BPH/LUTS). PCP is a new botanical drug candidate developed for the prevention of prostate cancer.

Webull offers Jyong Biotech Ltd. stock information, including NASDAQ: MENS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, MENS stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading MENS stock methods without spending real money on the virtual paper trading platform.